Completed PHASE2 INTERVENTIONAL 2-arm NCT00627432

Gemcitabine With Or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

Phase 2 Randomized Study Evaluating the Efficacy of Gemcitabine With or Without Oxaliplatin in Patients With Advanced Urothelial Cancer That Cannot be Treated With Cisplatin-based Chemotherapy

Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle

Conditions Bladder Cancer

Interventions gemcitabine hydrochloride oxaliplatin

Updated 6 times since 2017 Last updated: Feb 13, 2025 Started: Jul 31, 2004 Primary completion: Mar 31, 2009 Completion: Mar 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Bladder Cancer and is currently completed. Institut du Cancer de Montpellier - Val d'Aurelle leads this study, which shows 6 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Mar 2025 — Present [monthly]

Completed PHASE2

Status: Suspended → Completed
Sep 2024 — Mar 2025 [monthly]

Suspended PHASE2
Jul 2024 — Sep 2024 [monthly]

Suspended PHASE2
Jan 2021 — Jul 2024 [monthly]

Suspended PHASE2
Jun 2018 — Jan 2021 [monthly]

Suspended PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Suspended PHASE2

First recorded

Jul 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institut du Cancer de Montpellier - Val d'Aurelle

Data source: Institut du Cancer de Montpellier - Val d'Aurelle

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montpellier, France